Los Angeles Capital Management
STOK icon

Los Angeles Capital Management’s Stoke Therapeutics STOK Stock Holding History

Los Angeles Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
35,598
+5,119
+17% +$164K ﹤0.01% 709
2026
Q1 		$992K Buy
30,479
+21,273
+231% +$698K ﹤0.01% 686
2025
Q4 		$292K Sell
9,206
-57
-0.6% -$1.71K ﹤0.01% 1115
2025
Q3 		$218K Sell
9,263
-10,452
-53% -$179K ﹤0.01% 1246
2025
Q2 		$224K Buy
+19,715
New +$187K ﹤0.01% 1151
2025
Q1 		– Sell
-43,438
Closed -$479K – 1219
2024
Q4 		$479K Sell
43,438
-59,567
-58% -$732K ﹤0.01% 823
2024
Q3 		$1.27M Buy
103,005
+36,240
+54% +$513K 0.01% 571
2024
Q2 		$902K Buy
66,765
+4,508
+7% +$60.9K ﹤0.01% 686
2024
Q1 		$840K Hold
62,257
– – ﹤0.01% 746
2023
Q4 		$327K Buy
62,257
+14,510
+30% +$62K ﹤0.01% 990
2023
Q3 		$188K Sell
47,747
-1,330
-3% -$8.75K ﹤0.01% 1073
2023
Q2 		$522K Buy
49,077
+10,022
+26% +$107K ﹤0.01% 843
2023
Q1 		$325K Sell
39,055
-1,358
-3% -$12.3K ﹤0.01% 988
2022
Q4 		$373K Buy
40,413
+12,190
+43% +$127K ﹤0.01% 974
2022
Q3 		$362K Hold
28,223
– – ﹤0.01% 1024
2022
Q2 		$373K Buy
28,223
+5,210
+23% +$79.2K ﹤0.01% 1076
2022
Q1 		$484K Buy
23,013
+4,410
+24% +$88.3K ﹤0.01% 1046
2021
Q4 		$446K Sell
18,603
-1,484
-7% -$35.4K ﹤0.01% 1062
2021
Q3 		$511K Buy
20,087
+2,970
+17% +$82.8K ﹤0.01% 1034
2021
Q2 		$576K Buy
+17,117
New +$605K ﹤0.01% 1115

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Los Angeles Capital Management's STOK Position: Q2 2026 in Review

Los Angeles Capital Management increased its Stoke Therapeutics (STOK) stake by 17% in Q2 2026, buying an estimated $164K and bringing the position to 35,598 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #709.

Los Angeles Capital Management first reported a position in STOK in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.27M in Q3 2024. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Los Angeles Capital Management held 35,598 shares of Stoke Therapeutics worth $1.16M as of Q2 2026.
  • Los Angeles Capital Management bought 5,119 Stoke Therapeutics shares in Q2 2026, an estimated $164K.
  • Stoke Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #709 holding.
  • Los Angeles Capital Management first reported a position in Stoke Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Los Angeles Capital Management's Stoke Therapeutics position peaked at $1.27M in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.